Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.
Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.
Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.
Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.
For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.
Sensus Healthcare, Inc. (SRTS) reported strong financial results for Q2 2022, achieving revenues of $12.1 million, a 124% increase from Q2 2021. The net income for the quarter was $3.5 million, or $0.21 per diluted share, a significant turnaround from a net loss of $(0.3) million in the previous year. Adjusted EBITDA reached $4.7 million, compared to $(0.1) million in 2021. The company ended the quarter with $33.7 million in cash. Sensus affirms expectations for full-year profitability and highlights strong interest in its new TransDermal Infusion System™.
Sensus Healthcare (Nasdaq: SRTS) has sold 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC) in Texas, aimed at non-invasive hair health treatments. The first two systems will be delivered in Q3 2022, followed by the rest in Q4. This system enables painless delivery of U.SK Under Skin's Skin Savers Hair™ serum deep into hair follicles, enhancing patient satisfaction and treatment results. HEC has rapidly expanded from 2 to 9 clinics in 2022, providing hair loss treatments to millions of affected Americans.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 4, 2022, at 4:30 p.m. ET to discuss its second-quarter 2022 financial results. The management will also provide a business update and details on recent and upcoming milestones. The call can be accessed via phone or live webcast. Following the call, a replay will be available until September 3, 2022. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, featuring proprietary low-energy X-ray technology known as superficial radiation therapy.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.
On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.
Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.
Sensus Healthcare (Nasdaq: SRTS) recently announced successful treatments using its SRT-100 system, demonstrating its capability in veterinary oncology. A mata mata turtle at Denver Zoo was treated for squamous cell carcinoma, showing no signs of the lesion three months post-therapy. This follows earlier treatments on various animals at Colorado State University, expanding the application of SRT in veterinary medicine. The ongoing partnership with CSU aims to develop protocols and clinical data, highlighting potential growth in a new market segment.
Sensus Healthcare (Nasdaq: SRTS), a medical device company, is set to present at two investment conferences in March 2022. The 34th Annual ROTH Conference will be held from March 13-15, with a key ‘Fireside Chat’ on March 15 at 9:30 a.m. PT. Investors can access the chat and a pre-recorded presentation on the company's website. Additionally, Sensus will participate in the Maxim 2022 Virtual Growth Conference on March 28-29, joining an Aesthetic Device Industry Panel on March 28 from 1:00 p.m. to 2:30 p.m. ET.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is Sensus Healthcare, Inc.?
What products does Sensus Healthcare offer?
What is Superficial Radiation Therapy (SRT)?
Where is Sensus Healthcare based?
What recent collaborations has Sensus Healthcare announced?
How does Sensus Healthcare generate its revenue?
What is the Sentinel service program?
When is the next conference call for Sensus Healthcare?
Where can I find more information about Sensus Healthcare?
What conditions can Sensus Healthcare’s devices treat?
